Amgen, Inc. AMGN announced positive top-line results from a phase III study on Prolia for use in patients with glucocorticoid-induced osteoporosis. The study evaluated the efficacy and safety of ...

Treatment with denosumab 60 mg and 180 mg, with background methotrexate, reduces the progression of bone erosion according to results of a 227 patient-Phase II trial presented today at EULAR 2007 ...

Our news journalists obtained a quote from the research from Optum, "Potential denosumab 60 mg off-label use was observed based on claims, but many had evidence of on-label indications based on ...

--Amgen today announced results from a seven-year, single-arm, open-label extension of the three-year randomized, double-blind, placebo-controlled, multicenter, international Phase 3 F racture R ...

The US Food and Drug Administration (:FDA) recently granted approval to Amgen’s (AMGN) Prolia (denosumab) for an additional indication. Prolia can now be used as a treatment for increasing bone ...

Bird's group looked at Medicare data on women 65 and older who initiated treatment with denosumab 60 mg (n=1,523) or oral bisphosphonates (n=1,281) including alendronate (Fosamax), risedronate ...

In the first 2 years of the study, the women received 1 of 5 romosozumab regimens (70, 140, or 210 mg once monthly or 140 mg or 210 mg every 3 months) or placebo.

At month 15, patients who had received the high dose of teriparatide had an increase of 17.5% in spine BMD compared with 9.5% in the standard-dose group (P<0.001) as well as an increase of 6.1% in ...

Eligible women with hormone receptor–positive nonmetastatic breast cancer treated with adjuvant aromatase inhibitor therapy were stratified by duration of aromatase inhibitor therapy (≤ 6 v > 6 months ...

Amgen, Inc. AMGN announced positive top-line results from a phase III study on Prolia for use in patients with glucocorticoid-induced osteoporosis..